# Galena Biopharma

Source: https://onco.cc/companies/galena-biopharma/  
OnCo record `galena-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Galena was the company behind NeuVax, a HER2 peptide vaccine meant to stop early breast cancer returning; the phase 3 PRESENT trial was stopped for futility in 2016 and Galena merged into SELLAS.

## Summary

Galena Biopharma, founded in 2006 and headquartered in Portland, Oregon, developed nelipepimut-S (NeuVax), a HER2-derived E75 peptide vaccine given with GM-CSF to prevent recurrence in node-positive, HER2 low-expressing breast cancer. The phase 3 PRESENT trial was halted for futility in 2016; Galena merged with SELLAS Life Sciences in 2017. Its trials remain on ClinicalTrials.gov under Galena as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Galena Biopharma, Inc.; RXi Pharmaceuticals; SELLAS Life Sciences
- Tags: ctgov-sponsor
- HQ: Portland, OR
- Type: biotech
- Website: http://galenabiopharma.com

## Sources

- Official website: http://galenabiopharma.com
- ClinicalTrials.gov: trials led by Galena Biopharma, Inc.: https://clinicaltrials.gov/search?lead=Galena%20Biopharma%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q5518376

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/galena-biopharma.json